QuantuMDx and SCIENION Partner to Commercialize Novel Nanowire Biosensor
News Jun 09, 2015
QMDx utilizes SCIENION's proprietary ultra-low volume liquid handling technologies to transfer biological material onto QMDx's novel biosensor. Each nanowire in the array is printed with molecular probes; with hundreds of nanowires in each silicon biosensor chip, the multiplexing potential is massive.
The companies' longstanding relationship was cemented with QMDx's purchase of SCIENION's sciFLEXARRAYER SX, and will continue to grow as the companies embark on a number of development projects to take the biosensor characterization from R&D to mass manufacture.
The instrument is the newest fixture in QMDx's chemistry facility at the University of Newcastle upon Tyne's Chemical Nanoscience Laboratories.
QMDx's Head of Chemistry Dr Joseph Hedley said "The flexibility and ease of use of the sciFLEXARRAYER SX has enabled a rapid ramp up in QMDx's R&D activities, and we look forward to working with them on a number of exciting projects that will help bring this device to market."
"We're thrilled to be working with QuantuMDx" said Holger Eickhoff, CEO of SCIENION. "I look forward to our collaboration and believe that our work together will produce some fantastic developments that help foster some disruptive diagnostic innovations."
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative diseases in human brain tissue samples, including Alzheimer’s disease and chronic traumatic encephalopathy. Their discovery will help scientists develop targeted biomarkers and therapeutics, resulting in a more accurate diagnosis of complex brain diseases.READ MORE